Innoviva, Inc.
corporate_fare Company Profile
Innoviva, Inc. (NASDAQ:INVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for INVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for INVA spans 8-K, SCHEDULE 13D/A, 10-Q, 10-K/A.
Recent high-impact activity:
- Q3 Revenue Slips 1.6% as $139.5M Investment Write-Down Drives $73.9M Net Loss
- Innoviva Q2 Revenue Jumps 19% on 46% IST Sales Surge, Guides $150M+ for 2026
- IST Growth Lifts Innoviva Q2 Revenue 19%, but Investment Marks Drag Bottom Line
- Innoviva Provides Armata Pharmaceuticals with $25M Secured Loan at 14% Interest
- Innoviva Swings to Q1 Profit with $186.6M Net Income, $2.22 EPS on 11% Revenue Growth
Financial Snapshot
Short Interest & Short Volume
12.88 days to coverFINRA reported short interest of 7,495,210 shares in INVA as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 12.9 days to cover at its recent average daily volume. On November 20, 2026, 48.3% of INVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.